Management & Directors

JOHN A. LAWSON PH.D., Founder, Chairman & Chief Scientific Officer

Dr. Lawson is responsible for the planning of R & D and the supervision and execution of all chemistry activities related to drug discovery and development.


John Lawson is an expert in medicinal and synthetic organic chemistry. As a senior Medicinal Chemist and Project Manager at Stanford Research Institute (SRI International) for 20 years, he headed the Neurochemistry R & D Group with responsibilities for the discovery and development of new compounds in neuroscience area including analgesics, anti-convulsants, anxiolytics, and stroke. While at SRI, Lawson collaborated for ten years with Dr. Toll, Chief Neuropharmacologist and Board Member of Phoenix PharmaLabs (see below), on analgesic drugs under NIH grant funding. During this period, Dr. Lawson discovered the initial class of opioids capable of relieving pain without the typical side-effect problems of morphine-like opioids. After leaving SRI, Lawson assisted in the opening of a synthetic laboratory at SynVax, Inc., in northern Utah, for the purpose of developing and patenting new drugs related to Nociceptin -- a recently discovered brain chemical that modulates pain responses. Two years later, he left SynVax and founded Phoenix PharmaLabs, Inc. (PPL), for the purpose of renewing the development of non-addicting opioid compounds. John holds a BS degree with Phi Kappa Phi honors from Iowa State University and a Ph.D. from the University of Oregon. He was also a Postdoc. fellow at Syntex Corp.



WILLIAM CROSSMAN, President, CEO & Board Member

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.


Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 100 level companies. He has a proven track record of successfully commercializing emerging technologies. Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. These companies include Embedded Nanomagnetics, Inc. and Inframat Corp. (nanotechnology and life sciences), Intelepresence, Inc. (defense systems), Ensolve, Inc. (marine bioremediation products), Quantum Dynamics, Inc. (clean energy technology) and Frozen Process Technologies, Inc. (specialized manufacturing systems). As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth. The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.

TIMMY CHOU, Vice President, CFO and Board Member

Mr. Chou is responsible for the management of Company finances, corporate governance and treasury matters, including accounting and disbursements as well as the planning and execution of corporate development activities, including capital generation.

Timmy Chou’s corporate experience includes serving as a Chief Financial Officer, Controller, and CEO, as well as a management consultant for numerous companies. He is a founding partner of Spectra Consulting Group, where for more than 20 years he has performed consulting on growth issues in emerging businesses, including specialized consulting in strategic planning, cash management, capital structures, dispute mediation, and organizational re-engineering and process development. He is a serial entrepreneur and currently serves as an officer of several operating public and private companies and sits on various Boards as a director. He has participated in architecting numerous capital structures and has developed strategies for development-stage enterprises that have produced significant debt and/or equity investment. Mr. Chou is listed as an affiliate of the Wasatch Venture Network and is a member of the Association for Conflict Resolution and Utah Dispute Resolution. Timmy holds a bachelor’s degree from Brigham Young University and has pursued graduate work at the University of Utah. He also has completed training as a Microsoft Certified Systems Engineer, and completed graduate studies in mediation.


LAWRENCE TOLL PH.D., Founder, Chief Neuropharmacologist and Board Member

Dr. Toll is responsible for the planning of R & D strategies and the supervision and/or execution of discovery pharmacology activities related to the Company's drug development programs.


Dr. Toll is currently Director of Neuropharmacology, Torrey Pines Institute for Molecular Studies. Prior to that he was Director of the Neuropharmacology Department at SRI International, where he conducted basic and translational research in the fields of pain and addiction and also managed contract drug screening and other R & D services performed by teams of cellular, molecular, animal, and behavioral biologists. An author of more than 100 peer-reviewed scientific papers, he is a recognized expert and leading researcher in the field of neuroscience, particularly in relation to addiction neurobiology and the pharmacology of drugs with potential addiction liability, such as opiates. Dr. Toll is a co-discoverer of the “nociceptin” opioid peptide and was part of the Opiate Research team at SRI that first researched potential non-addicting opioids in the late 1980s. Dr. Toll has performed numerous selected assessments of neurochemical drugs for the National Institute on Drug Abuse (NIDA). As part of NIDA’s Opiate and Cocaine Treatment Discovery Programs, he tested a very large number of compounds for affinities and activities at the three opioid receptors, 5 dopamine receptors, several 5-HT receptors, PCP receptors and sigma receptors. In conjunction with this project and CPDD, Dr. Toll and his team published the definitive in vitro profile of opioid- and cocaine-related ligands. In addition to standard and unknown opiate-related compounds his lab has collaborated with many medicinal chemists to characterize the activity of a large number of compounds, including PPL's compounds. Larry holds a BA degree in chemistry from the University of California, San Diego and a Ph.D. in biological chemistry from the University of California, Los Angeles as well as a Postdoc. in biological chemistry at the University of California, Los Angeles and a Postdoc. in pharmacology at Johns Hopkins University.



CHRIS TEW, Vice President and Board Member

Mr. Tew is responsible for participating in the planning and execution of business development strategies and the active management of promotional and public relations activities and relationships as well as capital generation.

Chris Tew brings over 25 years of professional bioscience sales, marketing and business development leadership experience to the company as a sales, marketing and development executive with American Hospital Supply, CooperVision, and Alcon. Later, Mr. Tew joined Protocol Systems as Director of U.S. Sales during the company’s start-up phase soon becoming VP of Worldwide Sales. Mr. Tew played a pivotal role in driving global sales growth from $1.5 million to over $65 million when the company was sold. Mr. Tew participated in the process of taking the company public and later in completing the successful sale of the company for $145 million to Welch Allyn, Inc. Mr. Tew has been responsible throughout his career for championing many successful sales and product initiatives both inside and outside of these companies. In addition, Mr. Tew co-founded HealthWare Management Company, a healthcare software company, which was sold at a profit to Global Software. He continues to serve as a board member and in an advisory role to a variety of other companies. Chris holds a BA degree in mass communications from Brigham Young University, and completed an executive training program at Stanford University.


THEODORE H. STANLEY M.D., Consultant and Board Member

Dr. Stanley is responsible for advising the Company with respect to its business development, capital generation, and drug development strategies.

Dr. Stanley is a Professor of Anesthesiology at the University of Utah, where he has been employed for the past 30 years, and was the Chairman and Founder or ZARS Pharma, a Salt Lake City based pharmaceutical company focusing on opioid research and creative delivery methodology. Dr. Stanley was director of research at the University of Utah for over 20 years and is internationally known for his developmental work on opioids, other intravenous anesthetics and novel drug delivery techniques. In 1985, he co-founded Anesta, a drug delivery company with two FDA-approved products: fentanyl Oralet and Actiq. Dr. Stanley is an often invited speaker on Anesthesiology and the future of drug delivery topics throughout the world. Dr. Stanley was selected as the Utah Entrepreneur of the Year by the Wasatch Venture Group in 2006. Ted graduated from Columbia College and then Columbia University Medical School before completing a residency in anesthesiology at the Columbia-Presbyterian Medical Center.



News Flash

Phoenix PharmaLabs Releases New Data Confirming That Their Novel Opioid Shows No Signs of Addiction Potential


Phoenix PharmaLabs Releases New Data Confirming That Their <...
More details...

Novel Pinkiller with Little or No Signs of Addiction and Other Serious Opioid Side Effects Patented by Phoenix PharmaLabs


Novel Painkiller with Little or No Signs of Addiction and Other Serious Opioi...
More details...

Patent Awarded
"Use of PPL opiate in the treatment of opiate addiction." ...
More details...